Previous studies indicated that IL32 could bind integrin via its RGD motif to regulate breast cancer cell metastasis.[21] Notably, β5‐integrin is known to contain the RGD binding domain.[12, 20] We then investigated whether targeting β5‐integrin in cancer cells could reverse the paracrine effects of PCs on TKI drug sensitivity. The gene discussed is IL32; the disease is breast carcinoma.